Caris Life Sciences (CAI) Gross Margin (2024 - 2026)

Caris Life Sciences' Gross Margin history runs 3 years deep, the most recent figure standing at 79.16% for Q1 2026.

• In Q1 2026, Gross Margin rose 1210.0% year-over-year to 79.16%; the TTM figure through Mar 2026 stood at 80.96% (up 1474.0% YoY), while the FY2025 annual figure was 79.37%, up 1639.0% from the prior year.
• Gross Margin was 79.16% for Q1 2026 at Caris Life Sciences, down from 84.93% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 84.93% in Q4 2025 to a low of 61.31% in Q2 2024.
• Historically, Gross Margin has averaged 73.13% across 3 years, with a median of 73.91% in 2024.
• The sharpest annual moves came in 2025 and 2026: Gross Margin jumped 1714 bps in 2025, then jumped 1210 bps in 2026.
• A 3-year view of Gross Margin shows it stood at 71.12% in 2024, then climbed by 19 bps to 84.93% in 2025, then retreated by 7 bps to 79.16% in 2026.
• The last three Gross Margin figures came in at 79.16% (Q1 2026), 84.93% (Q4 2025), and 80.97% (Q3 2025), per Business Quant data.